| چکیده انگلیسی مقاله |
Abstract
Background: Breast cancer is the most common malignant disease among the female population of Kazakhstan like in many developed countries of the world (Canada, UK, US, Western Europe), and it accounts for every 5th tumor. We aimed to assess the epidemiological aspects of breast cancer incidence and mortality among Almaty and Astana (Now Nur-Sultan), Kazakhstan residents in 2009-2018.
Methods: A retrospective study using modern descriptive and analytical methods of epidemiology was conducted to evaluate the breast cancer incidence and mortality in megapolises of Kazakhstan.
Results: The average annual age-standardized incidence rate of breast cancer amounted to 61.90/0000 (95% CI=56.2-67.6) in Almaty and 61.20/0000 (95% CI=56.765.7) in Astana. The average age-standardized mortality was 19.20/0000 (95% CI=17.3-21.1) in Almaty and 19.30/0000 (95% CI=17.1-21.4) in Astana. The standardized incidence in the megapolises tended to increase (Тgr=+0.8% in Almaty and Тgr=+1.4% in Astana), while the mortality was decreasing (Тdec=−4.2% in Almaty and Тdec=−1.1% in Astana). According to the component analysis, the growth in the number of breast cancer cases was due to a population increase (ΔP=+130.4% in Almaty and ΔP=+93.2% in Astana), with a notable decrease of factors related to the risk of getting sick (ΔR=−27.9% in Almaty, ΔR=−6.1% in Astana).
Conclusion: This is the first epidemiological study to assess the changes in incidence and mortality from breast cancer in megapolises of Kazakhstan because of screening. The results of this study can be used to improve the government program to combat breast cancer.
|
| نویسندگان مقاله |
| Nurbek IGISSINOV
1. Department of Surgical Diseases Internship, Astana Medical University, Nur-Sultan, Kazakhstan 2. Department of Science and Analytic, International High School of Medicine, Bishkek, Kyrgyzstan 3. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan 4. Eurasian Institute for Cancer Research, Bishkek, Kyrgyzstan
| Assem TOGUZBAYEVA
Department of Public Health, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
| Botagoz TURDALIYEVA
Department of Science and Innovation, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan
| Gulnur IGISSINOVA
Department of Oncology, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan
| Zarina BILYALOVA
Central Asian Cancer Institute, Nur-Sultan, Kazakhstan
| Gulnur AKPOLATOVA
1. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan 2. Department of General and Clinical Pharmacology, Astana Medical University, Nur-Sultan, Kazakhstan
| Murat VANSVANOV
Department of Public Health with Nursing Course, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan
| Dinar TARZHANOVA
1. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan 2. Department of General and Clinical Pharmacology, Astana Medical University, Nur-Sultan, Kazakhstan
| Akmaral ZHANTUREYEVA
1. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan 2. Department of General and Clinical Pharmacology, Astana Medical University, Nur-Sultan, Kazakhstan
| Marina ZHANALIYEVA
1. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan 2. Department of Human Anatomy with Operative Surgery, Astana Medical University, Nur-Sultan, Kazakhstan
| Aigul ALMABAYEVA
1. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan 2. Department of Human Anatomy with Operative Surgery, Astana Medical University, Nur-Sultan, Kazakhstan
| Alikhan TAUTAYEV
1. Department of Surgical Diseases Internship, Astana Medical University, Nur-Sultan, Kazakhstan 2. Central Asian Cancer Institute, Nur-Sultan, Kazakhstan
|